drugset / Trial / NCT01786239
Omega-3 Dietary Supplements in Schizophrenia
Completed
50 enrolled
Delbert Robinson
National Alliance for Research on Schizophrenia and Depression · collabNational Institute of Mental Health (NIMH) · collab
RandomizedSingle-groupQuadruple-blindTreatment
Summary
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
Timeline
- Start
- 2013-05
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omega-3 fatty acids | Unknown | 400 mg | — |
| Subject | Omega-3 fatty acids | Unknown | 740 mg | — |
| Background | Risperidone | Other / unclassified | 1 mg | — |
| Background | Risperidone | Other / unclassified | 6 mg | — |